Levosimendan Orion Orion (Levosimendan)

Levosimendan works by binding to cardiac troponin C, which makes the heart muscle more responsive to calcium, thereby strengthening contractions without increasing calcium overload. At the same time, it opens ATP‑sensitive potassium channels in blood vessels, causing arterial and venous dilation that reduces preload and afterload.

The dosing regimen for levosimendan is individualized by the treating physician based on the patient’s clinical status, weight, and response. The prescriber determines the infusion rate, loading dose, and duration, following local guidelines and product labeling.

Safety data for levosimendan in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the prescribing clinician in consultation with the patient.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and required import documentation.

Unlike traditional catecholamine inotropes, levosimendan increases contractility without raising intracellular calcium, which may reduce the risk of arrhythmias. It also provides vasodilatory effects through potassium‑channel opening, offering a combined inotropic‑vasodilatory profile that can be advantageous in certain acute heart‑failure scenarios.

Levosimendan Orion should be stored refrigerated at 2‑8 °C, protected from light, and never frozen. The product must be kept in its original packaging to maintain stability, and any reconstituted solution should be used promptly according to the manufacturer’s instructions.

Levosimendan Orion is administered intravenously by a healthcare professional. It is typically given as an initial loading dose followed by a continuous infusion over several hours, with dosing adjustments made based on hemodynamic response and tolerability.

The most serious risks include severe hypotension, ventricular arrhythmias, and myocardial ischemia. Patients should be closely monitored for blood pressure, heart rhythm, and signs of chest pain during and after the infusion, and appropriate measures should be ready to manage these events.

Levosimendan is contraindicated in patients with severe aortic stenosis, uncontrolled hypotension, or known hypersensitivity to the drug or its excipients. Caution is also advised in patients with significant renal or hepatic impairment, and it should be avoided in those where the risk‑benefit ratio is unfavorable.